• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Deferasirox

Deferasirox

Product ID D1621
Cas No. 201530-41-8
Purity ≥99%
Product Unit SizeCostQuantityStock
25 mg $101.00 In stock
100 mg $371.00 In stock
250 mg $719.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Deferasirox is an iron chelator commonly used to treat iron-overload disease. Deferasirox also displays both neuroprotective and chemotherapeutic benefit as well. This compound exhibits neuroprotective activity in both in vitro and in vivo models of stroke/ischemia conditions. In vitro, deferasirox increases expression of metastasis suppressing genes, p21, caspase-3, and PARP and decreases levels of cyclin D1 and activity of NF-κB. The ability of deferasirox to inhibit iron uptake decreases tumor growth in animal models of cancer.

Product Info

Cas No.

201530-41-8

Purity

≥99%

Formula

C21H15N3O4

Formula Wt.

373.63

Chemical Name

4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]- benzoic Acid

IUPAC Name

4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2, 4-triazolidin-1-yl]benzoic acid

Synonym

ICL670A, CGP 72 670

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

D1621 MSDS PDF

Info Sheet

D1621 Info Sheet PDF

References

Vazana-Barad L, Granot G, Mor-Tzuntz R, et al. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma. Leuk Lymphoma. 2013 Apr;54(4):851-9. PMID: 23020673.

Lui GY, Obeidy P, Ford SJ, et al. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol. 2013 Jan;83(1):179-90. PMID: 23074173.

Zhao Y, Rempe DA. Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J Cereb Blood Flow Metab. 2011 Jun;31(6):1412-23. PMID: 21245873.

Messa E, Carturan S, Maffè C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010 Aug;95(8):1308-16. PMID: 20534700.

Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther. 2007 Oct;29(10):2154-66. PMID: 18042472.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • P0010

    Pituitary Adenylate Cyclase-activating Polypeptide-related Peptide, human

    Peptide, involved in paracrine and autocrine ce...

    ≥95%
  • D0363

    Daptomycin

    Anionic lipopeptide, alters cell membrane organ...

    ≥97%
  • S8047

    R,S-Sulforaphane, Research Grade

    Synthetic ITC.

    ≥97%
  • F5869

    N-formyl-Met-Ala-Ser

    Peptide, involved in neutrophil activation; FPR...

    ≥95%
  • C5592

    CNX-774

    BTK inhibitor.

    ≥98%
  • A6132

    Apicidin

    Cyclic tetrapeptide; HDAC inhibitor.

    ≥98%
  • A0977

    Actinomycin

    Polypeptide antibiotic produced from Streptomyc...

    ≥98%
  • R5992

    Roxithromycin

    Macrolide; protein synthesis inhibitor.

    ≥96%
  • C0267

    Carnosol

    Diterpene compound originally found in Rosmarin...

    ≥98%
  • P0246

    Palomid 529

    mTOR inhibitor.

    ≥98%
  • C104761

    CCT-196969

    pan-Raf inhibitor.

    ≥98%
  • V014463

    Valsartan Methyl Ester

    Valsartan impurity

    ≥98%
  • S8009

    Substance P (7-11)

    Endogenous tachykinin peptide, involved in infl...

    ≥95%
  • D5794

    Doxorubicin Hydrochloride

    Anthracycline, DNA intercalator; topoisomerase ...

    ≥98%
  • P2857

    Phorbol-12-myristate-13-acetate

    PKC activator, carcinogen.

    ≥98%
  • V3212

    Vidarabine

    Nucleoside (adenosine) analog; viral DNA polyme...

    ≥98%
  • A6978

    Artemisinin

    Sesquiterpene lactone found in Artemisia (wormw...

    ≥98%
  • S0245

    Salmeterol

    β2-adrenergic agonist.

    ≥98%
  • A5228

    Angiogenin

    Small protein, cleaves RNA.

    ≥98%
  • L960002

    LY-294002 Hydrochloride

    Inhibitor of PI3K.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only